MICHELLE SCHMALE: Open Payments
NPI 1588214217 · TOPEKA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$884 in 50 payments from 15 companies in 2025. Trend: 2023 $936 · 2024 $874 · 2025 $884
Food & beverage: $884
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $217 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $135 |
| QOL Medical, LLC | 5 | $121 |
| Madrigal Pharmaceuticals | 6 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Janssen Biotech, Inc. | 2 | $34 |
| GENZYME CORPORATION | 1 | $30 |
| Lilly USA, LLC | 1 | $24 |
| Novo Nordisk Inc | 1 | $24 |
Products named: XIFAXAN, SKYRIZI, Sucraid, REZDIFFRA, ENTYVIO, RINVOQ, DUPIXENT, IQIRVO.
Industry payments across KS — which companies pay providers there.
